Aveta Biomics selected Natera’s ctDNA test Signatera to measure minimal residual disease in its Phase 3 head and neck squamous cell carcinoma trial. The biomarker strategy uses Signatera across treatment as both a secondary endpoint and a way to further validate earlier Phase 2 ctDNA findings. The Phase 3 trial will enroll up to 826 patients randomized to APG-157 versus standard of care, with cohorts split between resectable and unresectable disease. Aveta said Signatera’s role is intended to generate molecular response data that can support regulatory submissions.